Rethinking CF organization of care in the era of highly effective modulator: a nationwide research program HORIZON
Author:
Affiliation:
1. INSERM U1290, Université Claude Bernard Lyon 1
2. Association Vaincre la Mucoviscidose
3. Hôpital Femme Mère Enfant. Hospices Civils de Lyon
Abstract
Highly effective modulator therapy (HEMT) is now available to a wider range of people with cystic fibrosis (pwCF). It has significantly improved short-term clinical outcomes and has the potential to alter the natural history of this fatal genetic disease. If long-term follow-up observational data is required to ensure clinical benefits, it is obvious that it will also change the needs of pwCF and the roles and missions of healthcare professionals (HCPs) in CF centers and beyond. We will conduct a nationwide research program called 'HORIZON' to support the necessary changes in the organization of CF care in the coming years. Our primary objective is to design a new model of CF care organization that can respond to the new needs and missions of pwCF and HCPs in this era of rapid and profound changes due to HEMT. This research program is based on the intervention mapping method, in which we will conduct the first four steps to design and plan the implementation of a new organization of care. The program will involve all stakeholders of the CF care network, including HCPs from CF care centers and outside, pwCF and their families, patient organizations, and experts from other countries. It will combine quantitative and qualitative research approaches and rely on an 'action research' method. Anticipating and supporting the reorganization of CF care in France requires a robust research program to find the best model that meets the expectations of all key stakeholders.
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. 1. Di Sant'Agnese PE, Andersen DH. Cystic fibrosis of the pancreas. Prog Pediat Study. 1948;(1 Vol.):160 − 76.
2. 2. Castellani C, Massie J, Sontag M, Southern KW. Newborn screening for cystic fibrosis. Lancet Respir Med. 2016;4(8):653 − 61.
3. 3. Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers. 2015;1:15010.
4. 4. Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65–124.
5. 5. Goetz DM, Savant AP. Review of CFTR modulators 2020. Pediatr Pulmonol. 2021;56(12):3595 − 606.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3